For clinicians and patients, the practical timeline matters: CagriSema is closer to potential approval (phase 3 complete), while amycretin's phase 3 is planned for 2026
Pregnancy and breastfeeding are periods where these therapies are generally deferred, since they are not studied in those groups, and anyone managing a serious or unstable medical condition should be evaluated and cleared before starting
Mcke M, Phillips T, Radbruch L, et al
Initially targeted towards Type 2 diabetes, the significant weight loss benefits observed with GLP-1 RAs such as semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda ) and tirzepatide (Mounjaro) have led to these treatments becoming blockbuster weight management therapies as well as effective diabetes medications
Thomas A, Grgens C, Guddat S, et al